{"schema_version":"1.0","type":"article","title":"From a Daily Tablet to Factory Orders: Who Can Profit from Oral Cyclic Peptides?","url":"https://drugnews.com.tw/articles/2026-10-05-cyclic-peptide-upstream-2026-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-10-05-cyclic-peptide-upstream-2026-en.md","lang":"en","date":"2026-10-05","publish_at":"2026-10-05T08:00:00+08:00","updated_at":"2026-10-05","category":"商業分析系列","topic":"商業分析系列","tags":["口服環肽","enlicitide","Orbis","Novo Nordisk","製程"],"summary":"On September 17, 2026, Novo Nordisk and Orbis Medicines announced a collaboration to develop oral macrocycles for cardiometabolic diseases. Upfront payments and potential development and commercial milestones total up to US$1.4 billion, with additional sales royalties; Novo will also make a strategic investment in Orbis. A large drugmaker is buying opportunities to discover new medicines. That headline ceiling is not yet an order held by a raw-material factory, and the announcement does not disclose commercial purchase volumes or suppliers.","key_points":[],"facts":[],"sections":[],"references":[],"images":[{"alt":"An unscored oval tablet, calendar and hypothetical population lead to the calculation. An equivalence bridge links 20 mg enlicitide to 22.21 mg decanoate salt and the corresponding 60 kg and 66.63 kg mass expressions.","url":"https://drugnews.com.tw/assets/articles/cyclic-peptide-upstream-2026-en/FIG01_EN_R2.png"},{"alt":"Assembled precursors lead either to cyclic product or unwanted oligomers. The high-dilution vessel contains the same connected precursors at greater separation, alongside solvent and equipment-use symbols.","url":"https://drugnews.com.tw/assets/articles/cyclic-peptide-upstream-2026-en/FIG02_EN_R3.png"},{"alt":"Engineered enzymes support fragment formation, coupling and macrocyclization followed by product crystallization. Protecting-group-free applies to these assembly steps, while step reduction and commercial costs are labeled separately. The title asks whether a shorter route could also change the upstream business.","url":"https://drugnews.com.tw/assets/articles/cyclic-peptide-upstream-2026-en/FIG03_EN_R5.png"},{"alt":"A neutral contract connects to product demand, deliverable capacity, process quality and supplier qualification by customers. Development services and material supply are presented separately below as different commercial arrangements.","url":"https://drugnews.com.tw/assets/articles/cyclic-peptide-upstream-2026-en/FIG04_EN_R2.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/cyclic-peptide-upstream-2026-en/FIG01_EN_R2.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-10-05）。From a Daily Tablet to Factory Orders: Who Can Profit from Oral Cyclic Peptides?。https://drugnews.com.tw/articles/2026-10-05-cyclic-peptide-upstream-2026-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-10-05-cyclic-peptide-upstream-2026.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}